No Picture
Boston Cambridge Biotech Trending News

OXURION to Present at the Ophthalmology Day at BTIG

Leuven, BELGIUM, Boston, MA, US – November 24, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio […]

No Picture
Boston Cambridge Biotech Trending News

Aura Biosciences to Participate at the 4th Annual Evercore ISI HealthCONx Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that Elisabet de […]

No Picture
Boston Cambridge Biotech Trending News

Biogen pulls PRIME designation for aducanumab in Europe; Merck closes merger with Acceleron

Following news last week that Biogen received “a negative trend vote” in Europe for its controversial Alzheimer’s drug aducanumab, the company has officially pulled out of the EU’s priority medicines scheme, known as PRIME. First […]

No Picture
Boston Cambridge Biotech Trending News

EyePoint Pharmaceuticals Announces Closing of $115.4 Million Public Offering

WATERTOWN, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced […]